Jun 15, 2026 06:30AM
Jun 15, 2026 06:30AM
May 6, 2026 04:18PM
Apr 2, 2026 07:30AM
Apr 2, 2026 07:30AM
Dec 16, 2025 12:18PM
Mar 20, 2025 04:22PM Context Therapeutics Reports Full Year 2024 Operating and Financial Results
Nov 6, 2024 04:06PM
Sep 23, 2024 07:31AM
Sep 23, 2024 07:30AM
Aug 7, 2024 04:17PM
Aug 1, 2024 07:31AM
Aug 1, 2024 07:30AM
Jul 11, 2024 10:30AM H.C. Wainwright Reiterates Buy Rating on Context Therapeutics (CNTX)
Jul 10, 2024 07:30AM
Jul 10, 2024 07:30AM
May 8, 2024 04:06PM
May 2, 2024 07:32AM
May 2, 2024 07:31AM
Apr 1, 2024 07:30AM
Mar 21, 2024 07:43AM Context Therapeutics Reports Full Year 2023 Operating and Financial Results
Nov 9, 2023 04:15PM
Jan 31, 2023 07:30AM
Jan 31, 2023 07:30AM
Jan 31, 2023 07:30AM
Jan 4, 2023 07:30AM
Jan 4, 2023 07:30AM
Nov 29, 2022 07:31AM Context Therapeutics (CNTX) Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
Nov 29, 2022 07:30AM
Nov 29, 2022 07:30AM
Sep 27, 2022 07:30AM
Sep 27, 2022 07:30AM
Dec 3, 2019 08:00AM
Nov 8, 2019 08:00AM
Sep 17, 2019 08:02AM Centrexion Therapeutics Corp. (CNTX) Reports Complete Patient Enrollment in VICTORY-3 Phase 3 Open-Label Clinical Trial of CNTX-4975
Sep 17, 2019 08:00AM
Sep 4, 2019 11:11AM
Sep 4, 2019 11:11AM
Sep 4, 2019 08:00AM
Jul 18, 2019 07:30AM
Jun 11, 2019 07:30AM
Jun 5, 2019 07:30AM Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal Clinical Trial of Repeat Doses of CNTX-4975 in Patients with Moderate to Severe Osteoarthritis Knee Pain
Apr 29, 2019 08:25AM
Mar 27, 2019 07:30AM
Mar 7, 2019 07:30AM
Dec 5, 2018 07:30AM

323,573 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All